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Background. Fatigue in patients with multiple sclerosis (MS) is highly prevalent and severely impacts quality of life. Recent
studies suggested that sleep-disordered breathing (SDB) significantly contributes to fatigue in MS. Study Objective. To evaluate
the importance of routine respirography in MS patients with severe fatigue and to explore the effects of treatment with continuous
positive airway pressure (CPAP). Patients and Methods. We prospectively assessed the presence of severe fatigue, as defined by a
score of ≥5.0 on the Fatigue Severity Scale (FSS), in 258 consecutive MS patients. Ninety-seven patients (38%) suffered from severe
fatigue, whereof 69 underwent overnight respirography. Results. We diagnosed SDB in 28 patients (41%). Male sex was the only
independent associate of SDB severity (𝑃 = 0.003). CPAP therapy in 6 patients was associated with a significant reduction of FSS
scores (5.8±0.5 versus 4.8±0.6, 𝑃 = 0.04), but the scores remained pathological (≥4.0) in all patients.Conclusion. Respirography in
MS patients with severe fatigue should be considered in daily medical practice, because SDB frequency is high and CPAP therapy
reduces fatigue severity. However, future work is needed to understand the real impact of CPAP therapy on quality of life in this
patient group.
1. Introduction
Although fatigue has been increasingly recognized over the
past two decades as one of the most frequent and most
debilitating symptoms in patients with MS, there are still
no insights into its neurobiological mechanisms, and current
treatment options are highly frustrating [1–4]. In clinical
practice, MS patients complaining about fatigue are usu-
ally first scrutinized for additional and potentially treatable
comorbidities, such as depression, pain, anemia, or sleep-
wake disturbances [5]. If there is no such cause of fatigue, the
patient is considered to suffer from “MS-related fatigue,” that
is, a disease-inherent symptom related to the underlying neu-
roimmunological and neurodegenerative processes, and off-
label symptomatic treatment with stimulants of the central
nervous system may be recommended [3].
Recently, the need to search for sleep-wake disorders
in MS patients has been reemphasized, as several groups
observed a significant correlation with fatigue [6–10]. Specif-
ically, sleep-disordered breathing (SDB) has been proposed
as a potential risk factor for fatigue in MS. In the last year, a
cross-sectional study in 48MS patients suggested a predispo-
sition for SDB [11], and two studies found that severe fatigue
in MS was significantly associated with SDB and respiratory-
related arousals [9, 12]. Furthermore, Coˆte´ et al. conducted
the first controlled, nonrandomized clinical treatment study
and reported a significant improvement of fatigue follow-
ing treatment of SDB and other sleep disorders [13]. Very
recently, Veauthier et al. were able to identify treatment of
sleep disorders in MS patients as independent predictor of
fatigue reduction [14].
Taken together, there is increasing amount of data sug-
gesting that SDB should be routinely screened for in all
MS patients with severe fatigue. We therefore prospectively
assessed the presence and severity of fatigue in consecutive,
unselectedMS patients seen in a tertiary center and suggesteds
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overnight respirography to MS patients with severe fatigue.
Patients with SDB were offered CPAP therapy. The main
purpose was to elucidate whether routine respirography can
be recommended as a screening method in MS patients with
severe fatigue and whether long-term CPAP therapy leads to
a clinically meaningful improvement of fatigue. In addition,
we aimed at examining potential predictive factors of SDB in
MS patients with fatigue.
2. Patients and Methods
This prospective study was conducted at the Neurological
Department of the Kamillus-Klinik in Asbach, Germany,
from October 2010 until March 2011. The study protocol has
been reviewed and approved by the local Institutional Review
Boards, and all patients gave written informed consent before
inclusion.
2.1. Subjects and Clinical Assessment. During the above-
mentioned period, we prospectively evaluated 258 consecu-
tive patients with multiple sclerosis (MS). The diagnosis of
MS was definite in each patient and was made according
to standard criteria [15]. The majority of patients suffered
from secondary progressive MS (87%) (SPMS), and 13% had
a relapsing remitting (RRMS) form. We measured fatigue
severity with the Fatigue Severity Scale (FSS), a self-
administered questionnaire with nine items which has been
validated for various neurological disorders including MS
[16, 17]. A final score greater than 4.0 is widely accepted
to indicate the presence of fatigue. For the purpose of
our study, we included only patients with severe fatigue
defined by a FSS score ≥5.0. The rationale for including only
patients with severe fatigue is given by the observation that
beneficial treatment effects of CPAP therapy are usually most
pronounced in patients with high levels of fatigue [18]. We
identified 97 MS patients with severe fatigue. Sixty-nine of
them agreed to undergo overnight respirography. We used
the Epworth Sleepiness Scale (ESS) to assess sleepiness, with
scores ≥10 indicating excessive daytime sleepiness (EDS) [19,
20]. Information on disease duration was taken from the
patients’ medical history.We estimated the severity of disease
disability using the Kurtzke Expanded Disability Status Scale
(EDSS) [21].
2.2. Sleep Studies. Overnight (from 10 p.m. to 6 a.m.) respi-
rography was performed using a portable device (EasyScreen
4.0, Respironixs, Germany), which measured nasal airflow,
pulse rate, arterial oxygen saturation (finger pulse oximetry),
and thoracic and abdominal movements. Respirography has
been validated previously in patients with ischemic stroke
[22]. Apnea was defined by a cessation of nasal airflow ≥10
seconds and hypopnea by a reduction of nasal airflow by
≥50% or ≥30%, when associated with an oxygen desaturation
≥4% [23]. Apnea-hypopnea index (AHI) was defined by
the mean number of apneas and hypopneas per hour. SDB
was diagnosed in patients with an AHI ≥ 5/h. SDB was
classified as mild (AHI 5–15/h), moderate (AHI 15–30/h),
and severe (AHI ≥ 30/h). Apneas were differentiated in
obstructive, mixed, and central apneas according to standard
criteria [23]. Apneas were obstructive if accompanied with
continuous respiratory effort, central if unaccompanied by
evidence of respiratory effort, and mixed if a central apnea
developed respiratory effort with evidence of obstruction
later in the apneic interval. A diagnosis of central sleep
apnea was made in patients, in whom >50% of all respiratory
events were central. In addition, calculation of the oxygen
desaturation index (ODI) was performed. The magnitude
of the oxygen desaturation considered for ODI was ≥4%.
The analysis was made automatically and corrected visually.
Titration of CPAP was performed during overnight video-
polysomnography. The optimal therapeutic pressure was
determined to eliminate snoring, apneic events with arousals,
and oxyhemoglobin desaturations in all body positions and
sleep stages. Patients received conventional CPAP therapy
(REMstar M series, Philips Respironics or SOMNOcom-
fort2, Weinmann). Reevaluation of FSS and ESS scores was
scheduled after a 6-month period of CPAP therapy, although
significant short-term relief of both fatigue and sleepiness can
be expected already after 3–6 weeks of CPAP therapy [18].
2.3. Statistics. Continuous data were expressed as means and
standard deviation (SD) and categorical variables as numbers
and percentage. All analyses were performed with the Sta-
tistical Package for the Social Sciences (SPSS, version 17.0).
For univariate analysis we used Student’s t-test (for numerical
scale variables) and 𝜒2-test (for nominal scale variables). To
identify predictors of SDB severity, we performed stepwise
multiple linear regression analysis for multivariate analysis,
with AHI as dependent variable and the following indepen-
dent variables: age, sex, disease duration, disease subtype,
EDSS, BMI, FSS, and ESS scores. Correlation analyses were
performed using the Spearman’s coefficient. Significance was
accepted at 𝑃 < 0.05.
3. Results
3.1. Demographic and Clinical Characteristics. Sixty-nine MS
patients with severe fatigue consented to overnight respirog-
raphy. The majority were female (70%); mean age was 49.8 ±
9.2 years (range: 21–75 years). BMI was 26.0 ± 4.9 (range:
17–40). Most patients were severely affected by the disease,
as reflected by a mean EDSS of 5.8 ± 1.4 (range: 1.0–8.5)
and mean disease duration of 13.7 ± 8.8 years (range: 1–33
years). The patient group that declined respirography (𝑛 =
28) showed similar demographic and clinical characteristics
(data not shown).
3.2. Sleep-Disordered Breathing. Overnight respirography
revealed a mean AHI of 9.3 ± 16.9/h and a mean ODI of
10.5 ± 14.7%. SDB was found in 28 MS patients (41%) and
was mild in 18 patients (26%), moderate in 3 patients (4%),
and severe in 7 patients (10%). SDB was obstructive in all but
one patient. MS patients with SDB were significantly older
(𝑃 = 0.01) and tended to be more often male (𝑃 = 0.06).
Likewise, AHI correlated with age (rho = 0.33, 𝑃 = 0.006) but
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Table 1: Demographic and clinical characteristics in severely
fatigued MS patients with and without sleep-disordered breathing.
No SDB (AHI < 5/h) SDB (AHI ≥ 5/h) P
n (%) 41 (59%) 28 (41%)
Female sex, n (%) 32 (78%) 16 (57%) 0.06
Age (y) 47.4 ± 8.3 53.3 ± 9.5 0.01
BMI 25.4 ± 5.2 26.8 ± 4.2 0.27
Disease duration (y) 13.8 ± 8.9 13.6 ± 8.8 0.92
Disease subtype 0.73
RRMS 3 6
SPMS 25 35
EDSS 5.9 ± 1.5 5.8 ± 1.3 0.79
FSS 5.7 ± 0.7 5.5 ± 0.9 0.36
ESS 9.4 ± 4.7 9.7 ± 3.8 0.79
EDS (ESS ≥ 10) 18 (44%) 17 (61%) 0.13
BMI: body mass index (kg/m2), EDS: excessive daytime sleepiness, EDSS:
Expanded Disability Status Scale, ESS: Epworth Sleepiness Scale, FSS:
Fatigue Severity Scale, RRMS: relapsing-remitting multiple sclerosis, SPMS:
secondary progressive multiple sclerosis.
not with EDSS, disease duration, or BMI. Table 1 provides the
remaining demographic and clinical characteristics (Table 1).
3.3. Excessive Daytime Sleepiness. The overall prevalence of
excessive daytime sleepiness in our patient group was high
(51%).The presence of excessive daytime sleepiness, however,
was similar between patients with and without SDB (61%
versus 44%, 𝑃 = 0.13). Even when comparing patients with
moderate-severe SDB and those without SDB, we did not
detect any differences in the prevalence of SDB (70% versus
44%, 𝑃 = 0.30). Similarly, there was no correlation between
ESS scores and AHI (𝑟 = −0.05, 𝑃 = 0.66).
3.4. Sex-Related Differences. The gender ratio (f : m) was
3.6 : 1 in patients without SDB, but the male proportion
significantly increased with more severe SDB (𝑃 = 0.005):
the ratio was 2.6 : 1 in mild SDB, 0.5 : 1 in moderate SDB, and
0.4 : 1 in severe SDB. BMIwas similar in bothmale and female
patients (25.3 ± 3.8 versus 26.3 ± 5.2, 𝑃 = 0.12), but AHI
was significantly higher in male patients (18.5 ± 24.7 versus
5.2 ± 9.9, 𝑃 < 0.001). Multiple regression analysis confirmed
that male sex was an independent associate of SDB severity
(𝑃 = 0.003). Figure 1 shows the different relative distribution
of SDB in male and female patients. Otherwise, the clinical
characteristics were similar in both sex groups (Table 2).
3.5. Evolution of FSS and ESS under CPAP Therapy. We
recommended CPAP therapy to all patients with an AHI ≥
10/h (𝑛 = 14). Nine patients agreed, but 3 of them did not
tolerate the device. The remaining 6 patients (2 with RRMS,
4 with SPMS) revealed a CPAP daily average adherence of
≥5 hours per night during the 6-month treatment. In these
patients, AHI decreased during CPAP therapy from 39.2 ±
26.3/h to 5.2 ± 3.6/h (𝑃 = 0.02), and the minimal SaO
2
improved from 71.5 ± 11.7% to 88.2 ± 1.9% (𝑃 = 0.02). EDSS
remained stable (6.3 ± 1.3 versus 6.3 ± 1.2). At followup after
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Figure 1:MaleMS patients with severe fatigueweremore frequently
affected by SDB than female MS patients with severe fatigue.
Table 2: Gender-related differences in MS patients with severe
fatigue.
Female Male P
n (%) 48 (70%) 21 (30%)
Age (y) 49 ± 9.3 51 ± 9.2 0.73
Disease duration (y) 14.4 ± 9.1 11.9 ± 7.7 0.16
Disease subtype 0.71
RRMS 7 2
SPMS 41 19
EDSS 5.9 ± 1.4 5.8 ± 1.4 0.78
ESS 9.7 ± 4.5 9.2 ± 3.8 0.65
EDS (ESS ≥ 10) 25 (52%) 10 (48%) 0.49
BMI 26.3 ± 5.2 25.3 ± 3.8 0.12
No SDB (AHI < 5/h) 32 (67%) 9 (43%) 0.06
AHI 5.2 ± 9.9 18.5 ± 24.7 <0.001
ODI 7.1 ± 7.9 18.1 ± 22.4 <0.001
SaO2 min (%) 78.9 ± 14.6 75.5 ± 19.1 0.58
AHI: apnea-hypopnea index, BMI: bodymass index, EDS: excessive daytime
sleepiness, EDSS: Extended Disability Status Scale, ESS: Epworth Sleepiness
Scale, ODI: oxygen-desaturation index, RRMS: relapsing-remitting multiple
sclerosis, SaO2 min: minimal O2 saturation, SDB: sleep-disordered breath-
ing, SPMS: secondary progressive multiple sclerosis.
6 months, CPAP therapy was associated with a significant
decrease of FSS scores (5.8 ± 0.5 versus 4.8 ± 0.6, 𝑃 = 0.04),
whereas ESS scores did not change (9.8 ± 3.5 versus 9.5 ±
3.0, 𝑃 = 0.61) (Figure 2). However, despite the significant
reduction of fatigue severity during CPAP therapy, FSS scores
remained pathologic (≥4.0) in all treated patients.
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Figure 2: Follow-up under long-term treatment with continuous positive air pressure (CPAP) reveals significant reduction of FSS scores but
not of ESS scores.
4. Discussion
Considering the increasing interest in SDB as a potential risk
factor for fatigue in MS, the primary goal of this prospective
investigation—so far the largest respirography study on
SDB in MS—was to understand whether routine overnight
respirography should be done in all MS patients with severe
fatigue.We found a SDB frequency of 41% amongMSpatients
with severe fatigue and demonstrated that CPAP therapy was
associated with a significant improvement of fatigue severity,
while sleepiness remained unchanged. Furthermore, only
male sex could be identified as an sindependent predictor
of SDB in MS patients with severe fatigue. Taken together,
these findings indicate that routine respirography should be
considered in this specific patient group, but future work is
needed to confirm our results and establish the exact benefit
of SDB treatment also in terms of quality of life.
Although the observed SDB frequency was rather high,
our study was not designed to estimate the prevalence of SDB
inMS or to compare its prevalence betweenMS patients with
and without fatigue, as we did not perform respirography in
MSpatientswith FSS scores<5.0 anddid not include a control
group.Moreover, comparison to other studies is hampered by
disparities of included patient cohorts, methodological and
technical differences, and heterogeneous definitions of SDB.
In this line, two recent studies on SDB and fatigue in MS
differedwith regard to the applied polysomnographic scoring
criteria: one group used the Rechtschaffen and Kales criteria
and the other study scored according to the 1999 American
Academy of Sleep Medicine Task Force [9, 12, 24]. The two
methods use different placement of EEG electrodes, which
may affect the scoring of respiratory arousals. Thus, several
reasons may account for the large discrepancy of reported
prevalence of SDB inMS patients with or without fatigue. For
instance, two earlier studies did not find any cases with SDB,
as defined by an AHI ≥ 5/h, among 37 and 10 MS patients,
respectively, although the majority of these patients suffered
from fatigue [25, 26]. On the other hand, Kaminska et al.
performed polysomnography in 37 MS patients with severe
fatigue, as defined by the same criteria as in our study, and
found severe SDB (AHI > 30/h) in 32%, relative to 8% among
25 MS patients without severe fatigue [12]. Using another
fatigue questionnaire, Veauthier et al. reported a SDB preva-
lence of 27% and 2.5% in 26 MS patients with fatigue and 40
MS patients without fatigue, respectively [9]. Finally, Braley
et al. reported a mean AHI of 17.0±18.8/h in 48MS patients,
a much higher number than in our study [11]. Overall, these
studies illustrate our uncertainty regarding prevalence and
severity of SDB in MS and its relationship to fatigue.
Six MS patients with SDB and severe fatigue showed
significant reduction of fatigue severity after 6 months of
CPAP therapy: FSS scores decreased from 5.8 ± 0.5 to 4.8 ±
0.6. In otherwords, long-termCPAP therapy resulted in a 17%
fatigue reduction. Our results are in line with the recent study
of Coˆte´ et al. who treated 17MSpatients with SDB and fatigue,
reporting a decrease of FSS scores from 5.0 ± 1.7 to 4.3 ± 1.7,
corresponding to a 13% amelioration [13]. In addition, the
reduction of mean FSS scores in both studies was >0.6, which
has been suggested by Putzki et al. as a “clinical significant”
improvement [27]. On the other hand, however, the final
FSS score was still above 4.0, which is a widely accepted
cut-off for fatigue [17]. Considering the high burden of MS-
related fatigue, any alleviation would certainly be desirable,
even if only marginal. However, by now we do not really
know to what extent the observed reductions of the FSS score
represent a benefit to affected patients, especially in terms of
quality of life. Worthy of mention, a multivariate analysis in
the study of Coˆte´ et al. failed to detect any improvement of
quality of life after CPAP therapy, as examined by the Physical
and Mental Component Summary Scale of the Short Form
(36) Health Survey (SF-36) [13]. The number of studies on
health-related quality of life in MS patients is very large, and
fatigue has been identified as an independent predictor [28–
30].Thus, the lack of improvement in quality of life challenges
the significance of CPAP therapy in MS-related fatigue. A
possible explanation could be that the level of depression,
which is an ever stronger predictor of quality of life in MS,
did not improve during CPAP therapy, thereby obscuring a
potential benefit [28–30].
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Additional considerations highlight the ambiguous rela-
tionship between fatigue and SDB in MS patients. First, we
currently lack any objective tool that enables us to quantify
fatigue. Thus, rating of treatment outcomes regarding fatigue
relies solely on subjective estimation. Second, and closely
related to the first point, a possible placebo effect cannot be
ruled out. As evidenced by a recent randomized, double-blind
controlled trial, the placebo effect of shamCPAP therapymay
be quite considerable: ESS scores decreased in the placebo
group from 15.2±4.0 to 11.9±5.9 (𝑃 = 0.001), corresponding
to an effect size of 0.82, but results of the Osler test did
not change [31]. Furthermore, the placebo group showed
also a significant improvement of several items of the SF-
36 [31]. Other groups confirmed this substantial placebo
effect of CPAP therapy on sleepiness and quality of life [32].
A few groups studied fatigue response to CPAP therapy
in SDB patients without underlying neurological disease,
generating similar results [33–35]. While most groups uni-
formly reported a significant improvement of fatigue during
CPAP therapy, the findings from 2 double-blind, randomized
controlled trials observed significant reductions of fatigue
scores also during placebo CPAP therapy [34, 35]. Recently,
Tomfohr et al. confirmed that long-term CPAP therapy
leads to a benefit on fatigue beyond placebo effects [18]. In
summary, these studies clearly illustrate the importance of a
randomized, placebo controlled trial in order to demonstrate
that the observed improvement of fatigue in MS after CPAP
therapy is more than a mere placebo effect.
An intriguing finding of our study is the lack of cor-
relation between sleepiness and SDB. Other groups made
similar observations in MS patients, regarding both subjec-
tive and objective measures of sleepiness [12, 36]. In general,
sleepiness is regarded as the main daytime consequence
of SDB, caused by repeated apnea-induced arousals, sleep
fragmentation, and reduced slow-wave sleep, and a marked
reduction of sleepiness has been demonstrated following
CPAP therapy [37]. The high prevalence of sleepiness in our
cohort and its persistence under CPAP therapy suggest that
SDB is not the main etiology of sleepiness in MS patients
with fatigue.The prevalence of most sleep-wake disturbances
in MS has been shown to be increased in MS compared
to the general population and may thus account for the
observed high prevalence of sleepiness [7]. On the other
hand, sleepiness and fatigue in MS—generally regarded as
two distinct symptoms—may share a common pathophysi-
ology. The observation that the correlation between FSS and
ESS scores in MS is much stronger than in subjects with
various sleep disorders is also supportive of this hypothesis
[38, 39].
Finally, our study demonstrates that sleepiness, BMI, and
disease severity are not useful predictors of SDB in MS
patients with severe fatigue. Conversely, male and elder MS
patients aremore likely to presentmoderate-severe SDB.This
illustrates that the presence of SDB among MS patients with
severe fatigue may clinically not appear as obvious as it is in
subjects with “classical” SDB.
We have to acknowledge several limitations. First of all,
the number of treated patients was small, making general
conclusions difficult. Second, we did not assess possible con-
founders, such as mood disorders, and did not measure the
effects of CPAP therapy on quality of life. Third, we did not
include a control group. Furthermore, the additional presence
of other sleep-wake disturbances has not been assessed.
The prevalence of most sleep disorders is increased in MS
patients [7], and effective improvement of fatigue in MS
patients may require tailored therapies of more than only one
sleep disorder [13, 14]. In particular, a recent meta-analysis
indicated that restless-legs syndrome is frequent in MS, with
reported prevalence of 12–58%, and restless-legs syndrome
appears to be associated with fatigue in MS [40]. Finally,
future studies should prefer polysomnography instead of
respirography, as the latter does not allow detecting apnea-
induced EEG arousals, and they might use additional fatigue
scales such as the Modified Fatigue Impact Scale (MFIS),
which has been shown to assess cognitive and psychosocial
functioning more accurately than the FSS [41]. Nevertheless,
we believe that our study provides an additional piece of
clinical experience to the current discussion on the role of
SDB in MS patients with fatigue.
In conclusion, our study confirms that SDB and fatigue
are associated features in MS and that SDB treatment leads
to a small yet statistically significant reduction of fatigue.
However, well-designed studies are needed to substantiate the
clinical relevance of this association, by proving that fatigue
reduction following CPAP therapy has a meaningful impact
on quality of life that goes beyond a mere placebo effect.
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